

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

31 May 2026

### Effect of daily consumption of probiotic yogurt on liver enzymes steatosis and fibrosis in patients with nonalcoholic fatty liver disease

#### Protocol summary

##### Study aim

If appropriate, it is recommended to use probiotic yogurt in the diet of patients with non-alcoholic fatty liver

##### Design

A clinical trial with a control group, parallel group, randomized groups, on 68 patients. Lottery container was used for randomization.

##### Settings and conduct

A controlled clinical trial will be performed at the Gastroenterology Clinic. Before the intervention, anthropometric indices, blood pressure, liver enzymes, glycemic index, insulin resistance, hepatic steatosis, liver fibrosis and lipid profile will be evaluated in all subjects. Individuals will be randomly divided into intervention and non-intervention groups. Intervention: 300 g daily probiotic yogurt for 12 weeks, control: 300 g normal yogurt daily for 12 weeks. The yogurts have the same color, shape, taste and smell are used so that the researcher and the patient are not aware of its type and only our distributor is aware of its type.

##### Participants/Inclusion and exclusion criteria

1. Patients with non-alcoholic fatty liver disease, 2. Aged 18-65 years, 3. Body mass index between 25-35 kg/m<sup>2</sup>. 4. Patients have a fixed plan for medication use during the last 3 months.

##### Intervention groups

Intervention: daily 300g probiotic yogurt for 12 weeks, control: 300g normal yogurt for 8 weeks

##### Main outcome variables

Steatosis, fibrosis and liver enzymes including ALT, AST and GGT.

#### General information

##### Reason for update

Recruitment start date delayed due to Covid-19 pandemic and changed to December 2021.

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20210201050210N1**

Registration date: **2021-04-19, 1400/01/30**

Registration timing: **prospective**

Last update: **2021-06-21, 1400/03/31**

Update count: **1**

##### Registration date

2021-04-19, 1400/01/30

##### Registrant information

###### Name

Sara Ebrahimi-Mousavi

###### Name of organization / entity

###### Country

Iran (Islamic Republic of)

###### Phone

+98 51 3761 3287

###### Email address

s-ebrahimim@razi.tums.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2021-12-06, 1400/09/15

##### Expected recruitment end date

2022-01-05, 1400/10/15

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

##### Scientific title

Effect of daily consumption of probiotic yogurt on liver enzymes steatosis and fibrosis in patients with nonalcoholic fatty liver disease

##### Public title

Effect of daily consumption of probiotic yogurt in patients with non-alcoholic fatty liver

## Purpose

Treatment

## Inclusion/Exclusion criteria

### Inclusion criteria:

Non-alcoholic fatty liver disease was approved by a gastroenterologist using fibroscan examination  
Individuals aged 20 to 60 years  
Patients have a fixed plan for medication use during the last 3 months  
Body mass index between 25 to 35 kg/m<sup>2</sup>

### Exclusion criteria:

Smokers  
History of alcohol consumption  
Adherence to a special diet in the last 3 months  
Pregnant or lactating women or those planning to get pregnant in the next three months  
Menopausal women  
Individuals with pathologic conditions affecting the liver, including acute and chronic hepatitis, viral hepatitis, liver transplantation, autonomic hepatitis, hemochromatosis, primary biliary cirrhosis, Wilson's disease, antitrypsin deficiency and thyroid disease  
People with lactose intolerance  
People taking antibiotics  
Patients taking medications affecting serum lipids  
Individuals taking multivitamin-minerals during the previous month  
Patients who have used any type of probiotic product in the last two months

## Age

From **20 years** old to **60 years** old

## Gender

Both

## Phase

N/A

## Groups that have been masked

- Participant
- Investigator

## Sample size

Target sample size: **68**

## Randomization (investigator's opinion)

Randomized

## Randomization description

Individuals will be classified based on age(20-40/40-60), gender (male/female) and BMI (25-30/30-35) into different blocks. To do randomization, an identification code will be given to each participant, and then the codes of each two participants with the same age, gender and BMI will be poured into the lottery container. Random allocation will be done by a person who is unaware of the study. The first code will be assigned to the intervention group, the second code to the control group and so other participants will be randomly assigned to the two groups

## Blinding (investigator's opinion)

Double blinded

## Blinding description

The shape, appearance, packaging, color and smell of both probiotic and non-probiotic yogurts will be quite similar. In addition, the person who provides yogurts to patients is aware of the type of yogurt, but the researcher and the patient are not aware of it.

## Placebo

Used

## Assignment

Parallel

## Other design features

## Secondary Ids

empty

## Ethics committees

### 1

#### Ethics committee

##### Name of ethics committee

Ethics Committee of Tehran University of Medical Sciences

##### Street address

First Floor, Faculty of Medicine, Building No. 1, North Door of the University, POURSINA St, GHODS St, ENGHELAB St

##### City

Tehran

##### Province

Tehran

##### Postal code

14155-6117

#### Approval date

2021-01-20, 1399/11/01

#### Ethics committee reference number

IR.TUMS.MEDICINE.REC.1399.1006

## Health conditions studied

### 1

#### Description of health condition studied

Non-alcoholic fatty liver disease

#### ICD-10 code

K76.0

#### ICD-10 code description

Fatty (change of) liver, not elsewhere classified

## Primary outcomes

### 1

#### Description

Hepatic steatosis

#### Timepoint

Beginning the intervention and 12 weeks later at the end of the intervention

#### Method of measurement

Fibro-scan

### 2

#### Description

Hepatic fibrosis

#### Timepoint

Beginning the intervention and 12 weeks later at the end of the intervention

### Method of measurement

Fibro-scan

### 3

#### Description

Liver enzyme (ALT, AST and GGT)

#### Timepoint

Beginning the intervention and 12 weeks later at the end of the intervention

#### Method of measurement

Blood sample

## Secondary outcomes

### 1

#### Description

Lipid profile (TG, Total cholesterol, LDL-c and LDH-c)

#### Timepoint

Beginning the intervention and 12 weeks later at the end of the intervention

#### Method of measurement

Blood sample

### 2

#### Description

Glycemic index (FBS, FBI, HOMA-IR and QUICKI)

#### Timepoint

Beginning the intervention and 12 weeks later at the end of the intervention

#### Method of measurement

Blood sample

### 3

#### Description

Weight

#### Timepoint

Beginning the intervention and 12 weeks later at the end of the intervention

#### Method of measurement

Scales

### 4

#### Description

Waist circumference

#### Timepoint

Beginning the intervention and 12 weeks later at the end of the intervention

#### Method of measurement

Tape meter

### 5

#### Description

Body mass index (BMI)

#### Timepoint

Beginning the intervention and 12 weeks later at the end of the intervention

#### Method of measurement

Formula (weight (kilograms) divided by the squared height (meters))

## Intervention groups

### 1

#### Description

Intervention group: They will receive 300g of probiotic yogurt enriched with Bifidobacterium lactis and Lactobacillus acidophilus strains daily for 12 weeks. Microbiological analyzes showed that the average colony content of both strains is  $10^6$  CFU / g.

#### Category

Rehabilitation

### 2

#### Description

Control group: Control group: 300g will receive conventional yogurt for 12 weeks

#### Category

Placebo

## Recruitment centers

### 1

#### Recruitment center

##### Name of recruitment center

Dr. Seyyed Moayed Alaviyan's clinic

##### Full name of responsible person

Sara Ebrahimi-Mousavi

##### Street address

No. 178, Corner of Shadab Crossroads, Above Taleghani, Sepahbod Gharani St., Ferdowsi Square

##### City

Tehran

##### Province

Tehran

##### Postal code

1417935840

##### Phone

+98 21 8890 7154

##### Email

alavian@thc.ir

## Sponsors / Funding sources

### 1

#### Sponsor

##### Name of organization / entity

Tehran University of Medical Sciences

##### Full name of responsible person

Dr. Sahraeiyan

##### Street address

Vice Chancellor for Research and Technology, sixth floor, Central University Organization, corner of Ghods Street, Keshavarz Blvd.

##### City

Tehran

**Province**

Tehran

**Postal code**

1417935840

**Phone**

+98 21 8163 3685

**Email**

vcr@tums.ac.ir

**Grant name****Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Tehran University of Medical Sciences

**Proportion provided by this source**

50

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding***empty***Country of origin****Type of organization providing the funding**

Academic

**Person responsible for general inquiries****Contact****Name of organization / entity**

Tehran University of Medical Sciences

**Full name of responsible person**

Sara Ebrahimi-Mousavi

**Position**

Master student

**Latest degree**

Bachelor

**Other areas of specialty/work**

Nutrition

**Street address**

No. 44, Hojjatdoost Alley, Naderi St., Keshavarz Boulevard

**City**

Tehran

**Province**

Tehran

**Postal code**

1417613151

**Phone**

+98 21 8895 5975

**Email**

Sara.mse95@gmail.com

**Person responsible for scientific inquiries****Contact****Name of organization / entity**

Tehran University of Medical Sciences

**Full name of responsible person**

Sara Ebrahimi-Mousavi

**Position**

Master student

**Latest degree**

Bachelor

**Other areas of specialty/work**

Nutrition

**Street address**

No. 44, Hojjatdoost Alley, Naderi St., Keshavarz Boulevard

**City**

Tehran

**Province**

Tehran

**Postal code**

1417613151

**Phone**

+98 21 8895 5975

**Email**

sara.mse95@gmail.com

**Person responsible for updating data****Contact****Name of organization / entity**

Tehran University of Medical Sciences

**Full name of responsible person**

Sara Ebrahimi-Mousavi

**Position**

Master student

**Latest degree**

Bachelor

**Other areas of specialty/work**

Nutrition

**Street address**

No. 44, Hojjatdoost Alley, Naderi St., Keshavarz Boulevard

**City**

Tehran

**Province**

Tehran

**Postal code**

1417613151

**Phone**

+98 21 8895 5975

**Email**

sara.mse95@gmail.com

**Sharing plan****Deidentified Individual Participant Data Set (IPD)**

Undecided - It is not yet known if there will be a plan to make this available

**Study Protocol**

Undecided - It is not yet known if there will be a plan to make this available

**Statistical Analysis Plan**

Undecided - It is not yet known if there will be a plan to make this available

**Informed Consent Form**

Undecided - It is not yet known if there will be a plan to make this available

**Clinical Study Report**

Undecided - It is not yet known if there will be a plan to make this available

**Analytic Code**

Undecided - It is not yet known if there will be a plan to

make this available

**Data Dictionary**

Undecided - It is not yet known if there will be a plan to make this available